Highlights Otsuka Holdings Co., Ltd.

Equities

4578

JP3188220002

Pharmaceuticals

Delayed Japan Exchange Other stock markets 06:30:00 12/03/2026 GMT			5-day change	1st Jan Change
11,020.00 ^JPY	+1.29%		+8.36%	+24.20%

03-04	Irlab Working to Secure Funding for Phase 3 Study of Mesdopetam - fc	FW
02-26	Irlab Receives $3 Million Milestone Payment Following Dosing in Phase 1b Study	FW

Highlights

02-13	Otsuka Holdings Co., Ltd. Announces Dividend for the Fiscal Year Ended December 31, 2025, Payable on March 30, 2026	CI
02-13	Otsuka Holdings Co., Ltd. Provides Earnings Guidance for the Second Quarter (Year to Date) and for the Year Ending December 31, 2026	CI
02-13	Otsuka Holdings Co., Ltd. Provides Dividend Guidance for the Second Quarter of Fiscal 2026 and Year Ending December 31, 2026	CI
02-13	Otsuka Holdings Co., Ltd. authorizes a Buyback Plan.	CI
02-13	Otsuka Holdings Co., Ltd. announces an Equity Buyback for 7,000,000 shares, representing 1.33% for ¥50,000 million.	CI
02-13	Japan Stocks End Week in Red As BOJ Hawk Flags Near-Term Rate Rise	MT
02-13	Otsuka Holdings Co Ltd to buy back up to 1.33% of own shares worth 50 billion yen	RE
02-13	Otsuka Holdings Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-13	Otsuka's Profit Climbs 20% in 2025	MT
02-04	HBM Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2025	CI
02-02	Otsuka Corporation Provides Dividend Guidance for the Second Quarter End of Fiscal Year Ending March 31, 2026	CI
02-02	Otsuka Corporation Provides Dividend Guidance for the Fiscal Year Ending March 31, 2026	CI
01-27	Cms announces selection of drugs for third cycle of the Medicare drug price negotiation program	RE
01-12	Ionis Pharmaceuticals, Inc. Provides Additional Updates on Key Milestones Expected in 2026	CI
12-28	Final dividend	FA
11-26	Otsuka Wins U.S. FDA Accelerated Approval for VOYXACT	MT
11-25	Otsuka Holdings Co receives FDA accelerated approval for Voyxact for proteinuria reduction in adults with primary immunoglobulin A nephropathy at risk for disease progression	RE
11-25	Fda approves use of Voyxact to reduce proteinuria in primary immunoglobulin	RE
11-25	US FDA approves Otsuka's drug for a type of kidney disease	RE
11-14	Ema's CHMP announces positive recommendation on extension of therapeutic indications for Koselugo	RE
11-10	Otsuka Pharmaceutical, Co. Ltd. Announces Findings from 12-Month Interim Analysis of Sibeprenlimab for the Treatment of Immunoglobulin A Nephropathy in Adults	CI
31/10/25	Otsuka Holdings Nine-Month Profit Rises 55%	MT
31/10/25	Otsuka Holdings Co., Ltd. Reaffirms Consolidated Financial Forecast for the Fiscal Year Ending December 31, 2025	CI
31/10/25	Otsuka Holdings Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
22/09/25	Otsuka Completes Transfer of MicroPort Stake Held By Medical Devices Unit	MT